Navigation Links
Nfocus Neuromedical Announces Acquisition of StarFire Medical
Date:3/6/2008

PALO ALTO, Calif., March 6 /PRNewswire/ -- Nfocus Neuromedical, Inc. announced today that it has completed the acquisition of StarFire Medical, Inc. StarFire Medical is a manufacturer of therapeutic implantable devices for interventional (minimally invasive) treatment of neurovascular disease.

The assets acquired include products such as the DSB (Detachable Silicone Balloon) and the NDSB (Non-Detachable Silicone Balloon), also known as the Endeavor Balloon Catheter, both of which have been cleared for marketing by the FDA and through CE marking in Europe. The DSB is a silicone balloon which is used to treat neurovascular fistulas and aneurysms through endovascular (less-invasive catheter) techniques. The DSB can be navigated to the site of pathology, inflated and detached to produce a permanent embolization for symptomatic carotid-cavernous fistulas and for aneurysm treatment through parent vessel occlusion. The NDSB is a soft silicone balloon attached to a very flexible microcatheter and is used for temporary and test occlusion during endovascular procedures.

The acquisition also included other neurovascular devices and Intellectual Property (IP) of StarFire. The remaining StarFire IP is focused on advanced intracranial aneurysm treatment devices that are in development.

"There has been strong physician interest in having access to these types of products in the United States," stated Martin S. Dieck, President and Chief Executive Officer of Nfocus Neuromedical. "The combination of StarFire's existing FDA-cleared devices and advanced aneurysm cover technology fits perfectly with the Nfocus product platform."

Hemorrhagic Stroke

Hemorrhagic stroke is a critical and often life-threatening event most frequently brought on by a rupturing aneurysm or other vascular malformation. In many cases, open surgery may not be ideal or even possible, but the alternative, current endovascular devices, may not provide permanent treatment. It is these critical and underserved patients and their physicians, the interventional neuroradiologist and neurointerventional surgeon, which Nfocus is committed to serve.

For more information about aneurysms and hemorrhagic stroke see: http://www.strokeassociation.org and http://www.snis.org

About Nfocus Neuromedical, Inc.

Nfocus is a neurovascular development, manufacturing and marketing company focused on treating hemorrhagic stroke. Current and future product programs are aimed at rapid treatment of aneurysms and fistulas in the brain. Based in Palo Alto, California, Nfocus is privately held and venture capital backed. See http://www.nfocusneuro.com for further information. Nfocus products will be used by physicians performing less-invasive surgery with endovascular catheters using a technique known as neurointerventional surgery.


'/>"/>
SOURCE Nfocus Neuromedical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nfocus Neuromedical Receives CE Mark for the CardioVasc(TM) Stent-Graft and Delivery System
2. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Cancer Indexes
3. Pharos Innovations Announces First Recipient of National Award for Achievements in Chronic Care Programs and Research
4. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
5. The Hain Celestial Group Announces the Acquisition of MaraNatha(R) and SunSpire(R) Brands
6. Cardiogenesis Corporation Announces Rescheduled Fourth Quarter and Full Year 2007 Earnings Release
7. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming SAWC Conference
8. Milestone Scientific Announces Chicago Dental Societys 143rd Midwinter Meeting Proved Successful
9. Zounds Hearing Enters Moorestown and Announces $225,000 Hearing Partnership With Twilight Wish Foundation
10. Pregis Announces Investor Conference Call to Review 2007 Fourth Quarter and Full Year Financial Results
11. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, the game-changing ... grand opening of the Sober College Robert Pfeifer Memorial Learning Center at its ... and was attended by an overwhelming amount of alumni, family, colleagues and friends ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time ... Winchester, Va. "I thought that if the nebulizer had a more child-friendly design, then ... them." , He developed the patent-pending NEBY to avoid the need to deliver medication ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... was set up in 2006 as a non-profit organization to unite pharmaceutical and ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 2016 Research and Markets has announced the addition ... report to their offering. ... The report also analyses the market by the following Technology Types: ... for the US, Canada , Japan ... Latin America , and Rest of World. ...
(Date:12/9/2016)... 9, 2016 aTyr Pharma, Inc. (Nasdaq: LIFE ... Physiocrine-based therapeutics to address severe, rare diseases, today announced that senior ... Prescriptions for Success Healthcare Conference at the InterContinental Barclay Hotel in ... 2016, at 4:20 p.m. ET. About aTyr Pharma ... aTyr Pharma ...
(Date:12/9/2016)... 2016  Forge Therapeutics, Inc. today announced a ... EVT, TecDAX, ISIN: DE0005664809) to advance its novel ... of bacterial infections including those caused by drug ... attractive antibacterial target for more than the past ... starting points has hampered its progress. Forge has ...
Breaking Medicine Technology: